A comprehensive review of upper reference limits reported for (high-)sensitivity cardiac troponin assays: the challenges that lie ahead

Cardiac troponins (cTn) are the preferred markers for the diagnosis of acute myocardial infarction (AMI). The guidelines recommend the use of the 99th percentile upper reference concentration of a healthy population as the diagnostic cut-off for AMI. However, a broad range of upper reference limits...

Full description

Saved in:
Bibliographic Details
Published inClinical chemistry and laboratory medicine Vol. 50; no. 5; pp. 791 - 806
Main Authors Cardinaels, Eline P.M., Mingels, Alma M.A., Jacobs, Leo H.J., Meex, Steven J.R., Bekers, Otto, van Dieijen-Visser, Marja P.
Format Journal Article
LanguageEnglish
Published Germany Walter de Gruyter 01.05.2012
Subjects
Online AccessGet full text
ISSN1434-6621
1437-4331
1437-4331
DOI10.1515/cclm-2011-0895

Cover

More Information
Summary:Cardiac troponins (cTn) are the preferred markers for the diagnosis of acute myocardial infarction (AMI). The guidelines recommend the use of the 99th percentile upper reference concentration of a healthy population as the diagnostic cut-off for AMI. However, a broad range of upper reference limits is still employed, complicating the diagnosis of AMI. This overview is meant to assist laboratory specialists to define an appropriate cut-off value for the diagnosis of AMI. Therefore, we provide an overview of the analytical performance and upper reference limits of seven (high-)sensitivity cTn assays: Roche high-sensitivity cTnT and ADVIA Centaur, Stratus CS, Dimension Vista, Vitros ECi, Access and Architect cTnI assays. It is shown that none of the reference populations completely met the guidelines, including those in package inserts. Forty percent of the studies collected less than the advised minimum of 300 subjects. Many studies (50%) did not report their inclusion criteria, while lower 99th percentile limits were observed when more stringent selection criteria were applied. Higher troponin cut-offs were found in men and elderly subjects, suggesting sex- and age-specific cut-offs would be considered. Therefore, there is still need for a large, rigorously screened reference population to more accurately establish cTn upper reference limits.
Bibliography:cclm-2011-0895.pdf
ark:/67375/QT4-5QQVGWN7-Q
Corresponding author: Marja P. van Dieijen-Visser, Department of Clinical Chemistry, Maastricht University Medical Center, PO Box 5800, 6202 AZ Maastricht, The Netherlands Phone: +31 43 3874694, Fax: +31 43 3874692
ArticleID:cclm-2011-0895
istex:A62CE3E5A5ABE8625F41475774A8A15A48FFBA22
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1434-6621
1437-4331
1437-4331
DOI:10.1515/cclm-2011-0895